Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Lymphoma 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Prostatic Neoplasms 32Lymphoma, Large B-Cell, Diffuse 29Lymphoma, Follicular 15Leukemia 15Lymphoma, Non-Hodgkin 13Hodgkin Disease 11Burkitt Lymphoma 10Leukemia, Biphenotypic, Acute 8Neoplasm Metastasis 7Recurrence 6Neoplasms 6Lymphoma, Large-Cell, Anaplastic 6Lymphoma, B-Cell 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Hemangioma 5Ovarian Neoplasms 4Multiple Myeloma 4Immunoblastic Lymphadenopathy 4Dendritic Cell Sarcoma, Interdigitating 4Metastatic Castration-resistant Prostate Cancer 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell, Marginal Zone 3Breast Neoplasms 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Neurotoxicity Syndromes 2

Interventions

Cyclophosphamide 45Prednisone 31N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 29Vincristine 28Doxorubicin 27Etoposide 22romidepsin 20Gemcitabine 18Lenalidomide 1610-propargyl-10-deazaaminopterin 16fludarabine phosphate 15Whole-Body Irradiation 15Peripheral Blood Stem Cell Transplantation 14Brentuximab Vedotin 13Azacitidine 13Mycophenolic Acid 12Dexamethasone 10Cyclosporine 10Bortezomib 10Alemtuzumab 10Rituximab 8fludarabine 7belinostat 7Methotrexate 6Cytarabine 6Busulfan 6Bendamustine Hydrochloride 6pembrolizumab 5denileukin diftitox 5Nivolumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × Prednisolone × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

NCT03586999 2024-10-29

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

University of Colorado, Denver

Phase 1/2 Completed
18 enrolled 14 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT00562068 2013-08-26

Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Unknown
30 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡